# PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

> **NCT00544219** · NA · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 156 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **PROCEDURE:** positron emission tomography

## Key facts

- **NCT ID:** NCT00544219
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-09
- **Final completion:** 2016-01
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544219, "PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00544219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*